生技产业产学研研发成果企业加值教育训练(二)1050628
| 生技产业产学研研发成果企业加值教育训练(二) 美国专利商标局有关生命科学专利标的适格性新例 (USPTO’s New Subject Matter Eligibility Examples for Life Sciences) 爲积极有效促进国内生技学研单位与新兴生技企业创新发展， 生技育成联盟服务平台整合市场分析、检验测试、临床试验、 |
¡执行单位：财团法人生物技术开发中心、惇安智慧财产管理股份有
¡举办日期：中华民国105年6月28日(二)，下午13:30 - 16:30
¡活动地点：南港生技育成中心大会议室 (台北市南港区园区街3号F栋17楼)
¡报名方式：线上报名，2016/06/27(一)止
¡报名网址：http://www.dcb.org.tw/
¡费用：免费
¡洽询专线：李佳玲 02-26558633 分机8006
¡议程：
| 时间 | 主题 | 主讲人 |
| 13:30-13:50 | 报到 | |
| 13:50-14:00 | 致欢迎词 | 南港生技育成中心 |
| 14:00-16:00 | 美国专利商标局有关生命科学专利标的适格性新例 –较有利于有关诊断方法及天然物发明专利申请的审查原则? (USPTO’s New Subject Matter Eligibility Examples for Life Sciences –Better guidance for pursuing diagnostic and “natural-product” based inventions?) | 主讲人(Speaker)： Dr. Y. Jenny Chen Wolf, Greenfield & Sacks, P.C. |
| 16:00-16:30 | Q&A | 主持人： 王惠玲顾问 惇安智慧财产管理股份有限公司 |
一、课程内容摘述:
题目：美国专利商标局有关生命科学专利标的适格性新例
–较有利于有关诊断方法及天然物发明专利申请的审查原则?
USPTO’s New Subject Matter Eligibility Examples for Life Sciences
- Better guidance for pursuing diagnostic and “natural-product” based inventions?
In view of the U.S. Supreme Court’s decisions in Alice, Myriad, and Mayo, the U.S. Patent and Trademark Office (“USPTO”) has issued a series of guidance on patent subject matter eligibility under 35 U.S.C. § 101, including the Interim Guidance on Subject Matter Eligibility issued in December 2014 and the follow-on Update on Subject Matter Eligibility issued in July 2015. In May 2016, the USPTO further provided new Subject Matter Eligibility Examples for life science inventions.
The May 2016 new examples illustrate the application of the “significantly more” and “markedly different” analysis to various aspects of life science inventions, including vaccine, diagnosis and treatment, dietary sweetener, screening for genetic alterations, paper-making machine, and hydrolysis of fat. The majority hypothetical sample claims provided in these new examples are considered as directed to patent eligible subject matter, providing teaching points for pursuing patent-eligible subject matter in common aspects of life science technologies.
These updated new examples are not binding law and may subject to revisions in compliance with federal courts’ further clarification of the parameters to patent eligibility. Nonetheless, such examples reflect the USPTO’s current positions with respect to the application of the patent eligibility requirement to life science inventions. They are useful guidance to patent prosecutors for drafting claims and responding to rejections under 35 U.S.C. § 101.
二、讲者资歷:
Dr. Y. Jenny Chen
Shareholder
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue | Boston, MA 02210-2206
617.646.8000 | 617.646.8646 fax
Email:Yahua.Chen@
Direct: 617.646.8372
Jenny Chen focuses her practice on U.S. and foreign patent prosecution and portfolio strategy, opinion work, due diligence, and post-grant matters such as interference, inter partes review, and reexamination. Jenny counsels clients in the areas of biological, medical, and pharmaceutical sciences. She has worked on projects related to biosimilars, diagnosis and treatment for various diseases, vaccine technologies, drug discovery, antibiotic biosynthesis, medical implants, gene- and cell-based therapies, pharmaceutical formulations, and herb extracts.
Prior to joining the firm, Jenny was an associate at Occhiuti Rohlicek & Tsao, LLP in Cambridge, MA, a law clerk and associate at Fish & Richardson, PC., Boston, MA, an intern at a pharmaceutical company, and an intern at Great Boston Legal Service. Jenny was previously a postdoctoral fellow in the laboratory of Dr. David Hafler at Brigham & Women’s Hospital, Harvard Medical School. Her research focused on T cell activity in autoimmune diseases such as Type I diabetes. Jenny received her Ph.D. degree from Baylor College of Medicine, specializing in molecular biology and pharmacology.
王惠玲顾问
董事长/总经理
惇安智慧财产管理股份有限公司
105台北市松山区敦化北路122号11楼
Email: [email protected]
王惠玲顾问具有二十余年之智慧财产相关工作经验，
王顾问现为国立阳明大学兼任助理教授，及经济部智慧财产局委託「
王顾问曾参与经济部智慧财产局发明审查基准研究计画案，
